[144] Ionis Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Ionis Pharmaceuticals Form 144 filing summary — This notice reports a proposed sale of 16,000 shares of the issuer's common stock through Stifel Nicolaus & Company, Inc. with an aggregate market value of $703,642.00. The sale is scheduled approximately for 08/18/2025 on Nasdaq. The filing lists prior acquisitions underlying the shares: an option exercise on 01/03/2022 totaling 28,869 shares, restricted stock units granted on 01/15/2017 for 7,537 shares, and restricted stock units on 01/15/2016 for 6,373 shares. The table for sales during the past three months shows Nothing to Report. Several identifying fields (filer CIK/CCC and the named person for whose account the sale is proposed) are not provided in the content.

Positive

• Transaction details disclosed: Class, broker, share count, aggregate market value, exchange, and approximate sale date are provided
• Acquisition history included: Dates and types of acquisition (option exercise and RSUs) and amounts are listed
• Broker identified: Stifel Nicolaus & Company Inc is named as the executing broker

Negative

• Identifying filer information missing: Filer CIK/CCC and contact fields are not provided in the content
• Named seller not provided: The "Name of Person for Whose Account the Securities are To Be Sold" field is blank in the supplied content
• Remarks and signature details incomplete: No signature, date of notice, or plan adoption/instruction date are present in the provided content

Insights

Securities Analyst

TL;DR: Form 144 discloses a planned sale of 16,000 Ionis shares via Stifel with clear acquisition history but omits filer identity and the named seller.

The filing supplies transaction-level detail needed for public notice: the class of security, broker, share count, aggregate market value, and the approximate sale date. It also traces the provenance of the shares through option exercise and restricted stock unit grants across three acquisition dates, which helps assess whether the shares are likely eligible for Rule 144 resale. The absence of the filer CIK/CCC and the explicit name of the person for whose account the sale is proposed reduces transparency for investors and market participants seeking to link the sale to an insider or other reporting person.

Compliance / Corporate Governance Expert

TL;DR: The notice meets basic disclosure elements but lacks key identifying information required for straightforward public tracking.

Form 144 contains the necessary securities and acquisition detail used to evaluate Rule 144 eligibility, including acquisition dates and payment nature. However, critical identifying fields appear blank in the provided content (filer identifiers and the person for whose account the sale is to be made). For compliance reviewers, those missing identifiers are material to determine insider status and to match this notice to other SEC filings. The filing does state the mandatory representation regarding absence of undisclosed material adverse information and includes the broker name and intended exchange.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Stifel Nicolaus & Company Inc 501 N Broadway St. Louis MO 63102	16000	703642.00	159391229	08/18/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/03/2022	Option Exercise	Issuer			28869	08/18/2025	Cash
Common Stock	01/15/2017	Restricted Stock Units	Issuer			7537	01/15/2017	Cash
Common Stock	01/15/2016	Restricted Stock Units	Issuer			6373	01/15/2016	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Ionis Pharmaceuticals' Form 144 (IONS) report?

The filing reports a proposed sale of 16,000 shares of common stock through Stifel Nicolaus & Company Inc with an aggregate market value of $703,642.00, scheduled approximately for 08/18/2025 on Nasdaq.

When and how were the 16,000 shares acquired according to the filing?

The filing lists underlying acquisitions: 28,869 shares from an option exercise on 01/03/2022, 7,537 RSU shares on 01/15/2017, and 6,373 RSU shares on 01/15/2016.

Does the Form 144 show any sales by this person in the past three months?

The filing states Nothing to Report for securities sold during the past three months.

Which broker will handle the sale listed on the Form 144?

The executing broker named in the filing is Stifel Nicolaus & Company Inc, 501 N Broadway, St. Louis, MO 63102.

Are there any compliance or disclosure gaps in the provided Form 144 content?

Yes. The provided content does not include the filer CIK/CCC or the explicit name of the person for whose account the securities will be sold, which are material identifiers for public tracking.